Buprenorphine depot (Camurus)

丁丙诺啡（Camurus）

Report date: 2025/03/22 20:00:05

Base Information

Drug NameBuprenorphine depot (Camurus)
Drug Alias NamebuprenorphinumbuprenorfinaBrixadi (buprenorphine) extended-release (Camurus)BrixadiCAM-2048 +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMu opioid receptor agonistsKappa opioid receptor antagonists
TargetsMu opioid receptorKappa opioid receptor
Therapy Area/IndicationsOpioid-Related DisordersChronic PainBack Pain +[4] 
Global Approved IndicationsPain
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2018/12/21
Country/TerritoryUnited StatesSwedenTaiwan +[8] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesCamurus Ab
China Registration ClassN/A

Develop Information

Active CompaniesYale UniversityBraeburn Pharma Inc
Inactive CompaniesCamurus AbBraeburn Pharmaceuticals
Active IndicationsOpioid-Related DisordersPain
Inactive IndicationsChronic PainBack Pain

Other Information

ATC CodeN02AE01N07BC01
Related LinksWikipediaDrugBankKEGG